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PSYCHOBIOLOGY AND THERAPEUTIC APPROACHES 
TO ANXIETY STATES 
N. PRADHAN • 
SUMMARY 
The- current psychobiology and the therapeutic principles of anxiety itatrs have been reviewed. The 
ifpro-hippocampal system probably operates as the organ of match-mismatch comparator. A dysfunction of this in-
ternal comparator could possibly be the source of anxiety. There seem to be two distinctpsychobiologic models for 
njnu disorder and chronic anxiety state. The therapeutic responses of panic disorder toTC'A and MAOI and the re-
sponse ot the chronic anxiety state to benzodiazepines supports the classification ot two distinct syndromes. Ho-
wever different provocative challenge tests have not clearly delineated the role of nor-adrenergic (Nl) me< hanisms 
in panic disorder and benzodiazepine receptor theory for chronic anxiety state. Challenge tests with receptor ipecif-
IC pharmacologic agents may reveal the molecular basis of these disorders unlike the tests with non-specific agents 
like lactate and caffeine. 
Introduction 
The phenomenon of anxiety is universal 
to conscious existance. It is closely linked to 
fear in the phylogenetic evolution of af-
fects. Like any other affect, it is best ex-
pressed in human beings. A variety of 
stressful life situations may bring about an-
xiety. Anxiety may be considered as a phy-
siological reaction to stress. In the domain 
of stress adaptive reactions it bifurcates to 
fear, rage or withdrawal. Hence, it could be 
considered as a very primary affect precon-
dition to life. 
A quantitative or qualitative deviation 
from normal stress anxiety relation may be 
viewed as a formal definition of clinical or 
pathological anxiety. There are various dis-
criptive and phenomenological models of 
anxiety and its subtypes. These do not fall 
into the purview of the present paper. It is 
pertinent to mention that in all experi-
mental studies, only the somatoautonomic 
component is considered to be identical to 
manifest anxiety. It is more appropriate to 
confess that the important and fundamental 
"psychic" component of anxiety is closely 
linked to ontogeny of mind and conscious-
ness and remains beyond the scope of pres-. 
ent day Biology. Therefore, only a modest 
attempt is made to understand the neuro 
biologic substrate of anxiety and principles 
of Pharmaco-therapy. 
Neurobiologic Substrates of Anxiety 
It has been estimated that at least 2-5% 
suffer from anxiety disorders in the general 
population and the morbidity associated 
with it is about 75 %. There have been vari-
ous objective and psycho-physiologic mea-
surements of anxiety in last 20 years (Gran-
ville-Grossman 1971). These are of value in 
assessing anxiety, but of little theoretical 
significance. There appears no psychophy-
siologic or biochemical measure that is spe-
cific to this illness (Ladcr 1972, Tyrer arfd 
Lader 1976). During last decade, advances 
in basic neurosciences and experimental 
clinical researches (by the use of provoca-
tive (challenge) tests) have implied the role 
of NE (norepinephrine), benzodiazepine 
receptors, endogenous opiates, purines and 
GABA (gamma aminobutyric acid) in the 
cause and treatment of anxiety (Braestrup 
and Nielsen 1983. Redmond 1979,Tallman 
et al. 1980, Phillis and Wu 1981). The neu-
ral substrates like amygdaloid nucleus, me-
dial dorsal nucleus of thalamus, posterior 
hypothalamus, mamillary body and the scp- * 
tohippocampal system have been implied 
to generate and express anxiety. The scpto-
hippocampal system probably operates as 
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the organ of hesitation and doubt by the 
process of match-mismatch comparison 
(Shaw et al. 1982). It is the basis of conflict-
punishment paradigm in the evaluation 
of anxiolytic drugs and could possibly be 
the sheet of anxiety if it becomes overac-
tive. 
Pkarmacologic models of anxiety 
The Pharmacologic models of anxiety 
and panic disorders are based on the thera-
peutic consideration's and the challenge 
tests conducted with the use of (DL)-Lac-
tate, yohimbine, isoproterenol and other 
agents. Selective benzodiazepine receptor 
blockers have been used as challenge 
agents' in volunteers. The sodium lactate 
infusion elicits panic reactions that are 
claimed to mimic natural panic attacks in 
susceptible persons (Gorman et al. 1985, 
Liebowitz et al. 1984). Following treat-
ment by MAOI (Monoamine oxidase inhi-
bitors) or TCA (Tricyclic antidepressants) 
the lactate response turns to control levels 
(Kelly et al. 1971). The lactate model sug-
gests the involvement of underfincd regu-
latory abnormalities. It may be useful in 
identifying patients responsive to TCA and 
not be benzodiazepines (Rifkin et al. 1981). 
There are evidences for hyperactive adre-
nergic mechanisms in panic disorders. It is 
seen that imipramine and phenelzine re-
duce the frequency of panic attacks (Zitrin 
et al. 1983). Tricyclic antidepressants af-
fecting both serotonergic and nor adrenerg-
ic systems arc equally effective as antipanic 
agents. In contrast, the benzodiazepines 
that are highly effective in treatment of ge-
neralised anxiety and nervous disorders do 
not appreciably alter the course and out-
come of panic disorders. Also the treatment 
of generalised anxiety by TCA appears li-
mited. Down regulation of Beta receptors 
and up regulation of a, receptors occurs 
with chronic administration of TCA and 
MAOI (Susler 1981). There occurs also 
down regulation of a2 receptors by some 
TCA and MAOI drugs (Chamcy et al. 
1981) Beta receptor down regulation ap-
pears to be linked to a general effect of anti-
depressive therapies, but it is not yet clear 
which effect is possibly linked to antipanic 
activity. However, TCA and MAOI reduce 
NE turnover and yohimbine that produces 
panic attack by its a2 antagonism, increases 
NE turnover. Chronic alprazolam and imi-
pramine administrations and yohimbine 
challenge also suggest the role of 24 recep-
tors in panic disorders (Charncy et al. 1984 
1985). Buspirone, a non benzodiazepine an-
xiolytic that increases locus ceruleus firing 
does not have a satisfactory explanation on 
its mechanism of action (Sangera et al. 
1983). Therefore, a reduced a2 autoreceptor 
sensitivity, increased activity of excitatory 
inputs or reduced inhibitory input may lead 
to the common manifestation of increased 
NE turnover in anxiety and panic states. 
The reduction of a2 receptors by imipram-
ine appears contradicting to already re-
duced a2 receptor binding in platelets (Vc-
tulani et al. 1980). 
The other competitive but not mutually 
exclusive hypothesis of anxiety is based 
upon the benzodiazepine receptors which 
mediate the anxiolytic effect of benzodia-
zepines by potentiating the inhibitory GA-
BA-ergic mechanism through the effect on 
a chloride ionophore (Skolnick et al. 1982, 
Paul et al. 1981). The benzodiazepine re-
ceptors have been found in hippocampus, 
olfactory bulb, thalamic nuclei and cortex 
and are widely distributed in nature even in 
schistosomes. The benzodiazepine antago-
nists (active), Beta carbolines (CCE and FG 
7142) are anxiogenic. However, the drug 
RO-15-1788 though a benzodiazepine an-
tagonist do not possess anxiogenic activity. 
Therefore, the benzodiazep ine receptors 
not only mediate anxiolytic effect but may 
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luscl et al. 1984, Ninan et al. 1982, Lippa et 
jl. 1978). There exists a possibility of an en-
Jogciious benzodiazepine receptor hgand 
in the brain. At this time it is not under-
stood how anxiety is related to benzodia-
zepine receptor-GABA mediated system 
and its links to nor-adrenergic, enkephalin 
and serotonergic systems. Molecular phar-
macology in ruture may elucidate the basic 
mechanisms mediating the anxiety reac-
tion. 
principles of pharmaco-therapy of 
anxiety states 
Various modes of treatments are. avail-
able for this common disorder like psycho-
therapies, bio-feedback and meditations. 
The treatment effects are highly dependent 
upon personality factors such as suggestibil-
ity, level of intellectual sophistication and 
the individual value systems. Although the 
efficacy or traditional psychotherapies and 
imxlern, fashionable non-pharmacological 
methods cannot be dismissed, the very un-
verifiablc nature of the process prohibits 
anv scientific enquiry into these methods. 
Similarly, the undisputed utility of beha-
viour therapy in circumscribed phobic dis-
orders leads to erroneous generalisation of 
deconditioning molecular recognisation. 
Hence it is imperative to restrict the discus-
sion to the principles of current pharmaco-
therapy of anxiety disorders. 
Anxiolytic drugs are substances which 
reduce pathological anxiety, tension and 
agitation without therapeutic effect on 
cognitive or perceptual process. Most of 
these drugs are also potent anticonvulsants, 
sedatives and hypnotics. The barbiturates, 
meprobamates and other non benzodiaze-
pine minor tranquilisers have anxiolytic 
properties. However, most important 
group is benzodiazepines which arc remar-
kably non toxic and much less toxic that 
barbiturates. Meprobaniate, much used in 
1950's and 1960's but without a known me-
chanism of action, miscellaneous drugs 
such as Beta-blockers and some neurolep-
tics and antidepressants possessing anxio-
lytic properties, are not usually considered 
as true anxiolytics. The present day defini-
tion of an anxiolytic predominantly rests on 
anticonflict test. It is a selective action of 
benzodiazepine receptors and pharmacolo-
gical specificity of benzodiazepines. Cat 
muscle relaxation inhibition of pentazole 
convulsions ui mice, inhibition of mouse 
rotarod performance, inhibition of electric 
shock induced fighting in mice, inhibition 
of experimental human anxiety and resto-
ration of hehaviour suprcssed by puni-
shment indicative of anxiolytic effect in 
man are all correlated with the affinity for 
these receptors (Baestrup 1981). However, 
as the neurochemical basis of human anxie-
ty states remains uncertain the recent ap-
proaches to pharmacotherapy can be consi-
dered empirical in a limited sense. 
From the preceding sections it is clear 
that panic disorders are best treated by 
TCA, MAOI and the chronic nervous 
anxiety by benzodiazepines. Beta-blockers 
can be considered as broad spectrum anxio-
lytics effective in both panic disorders and 
chronic anxiety states, however, the 
response is less pronounced than other 
agents. 
Benzodiazepines 
In search for a novel group of CNS act-
ing drugs the 1-4 benzodiazepines were 
discovered by Sternback and Rceder in 
1961 by ring enlargement of biologically 
inactive qumazoline-N-oxide with mc-
thylaminc. Thus the 7-chloro-2 mcthyla-
mino-5 phenyl-3H-l, 4 bcnzodiazepinc-4 
oxidc-(Chlordiazcpoxidc) was born and 
other derivatives followed. For the bio-
logic activity the 1, 4-bcnzodiazcpines 
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and phenyl group at position 5 are essential. 
Roughly all drugs in this class possess 
anxiolytic, hypnotic, sedative and anticon-
vulsive properties notwithstanding the fact 
that they are promoted for different indica-
tions. The Pharmacokinetic differences are 
only important to their clinical activity. 
Except absorption, all clinical aspects can 
be correlated to the type of metabolic 
change the drug undergoes. Chlorazepatc 
and diazepam are rapidly absorbed. Other 
benzodiazepines are intermediate in time 
for absorption. Desmethyldiazepam has an 
average half life of 50 hours. Only 40% of 
diazepam remains unchanged and other-
wise diazepam, chlorazepatc, halazcpam 
and prazepam are converted to desmethl-
diazepam. Therefore, chlorazepate, halaze-
pam and prazepam are just prodesmethyl-
diazepam which is inturn converted to oxa-
zepam. Chlordiazepoxide is converted to 
desmethyl chlordiazepoxide - desmcthyl 
medazepam- dismethyl diazepam - de-
moxapam - oxazepam. 7 hcrefore, the drug 
takes longer time, 2-3 weeks to attain 
a steady state in slow metabolisers and its 
effective half life is about 10-40 hours. 
Drugs like Cimetidine, Disulfiram, Isonia-
zid and Oestrogcns that impair hepatic oxi-
dation can increase plasma levels of these 
drugs Oxazepam and Lorazepam are di-
rectly converted to glucoronic conjugates 
and are excreted, therefore they have very 
short half lives. All benzodiazepines have 
high therapeutic index. Tolerance and de-
pendence to these agents have been de-
monstrated (Shadcr 1978, Marks 1978 & 
Hallister 1978). Physical dependence can 
develop if excessive dosage of benzodia-
zepine arc used for a long time in patients 
with unstable personalities. Sudden withd-
rawal of benzodiazepine that are directly 
conjugated may result in withdrawal symp-
toms and rebound anxiety in patient (Fon-
taine et al. 1985, 1984). Paradoxical reac-
tions, rage reaction, disinhibitions have 
been reported. Even tolerance to model an-
xiolytic activity occurs in animals (Stephen 
and Schneider 1985). 
Tricyclic Antidepressants (TCA) and Monoa-
mine Oxidase Inhibitors (MAOI) 
More than 60 antidepressant drugs have 
been marketed since imipramine was first 
introduced in 1957. In the preceding sec-
tion it has already been suggested that TCA 
and MAOI are effective as antfpanic agents. 
Seven double blind trials have compared 
TCA (imipramine) with placebo in panic 
disorders and six have shown IM1 to be su-
perior to placebo (Marks et al. 1983). 
Few studies have shown MAOI to be effec-
tive in panic disorders (Sheehan et al. 1980). 
There are evidences that TCA are also ef-
fective in generalised anxiety disorder but 
evidence is not so clear in phobic neurosis 
(Klein 1974). Abrupt TCA withdrawal may 
produce symptoms of anxiety (Charney et 
al. 1980). The effect of new antidepressants 
on panic disorders is not evaluated. There 
are now selective MAO inhibitors-clorgyi-
ine is MAO-A selective and selegiline is 
MAO-B selective. Selegiline is marked for 
dopamine enhancing action in parkinsons 
disease. The dangerous food and drug inte-
ractions characteristic of the other MAOI is 
not usually found in selective MAO (B) 
bljckers. It appears that only those drugs 
which arc MAO (A) selective carry these 
risks. The new 5 HT selective drug 
Zimeldine has been withdrawn because of 
its neurotoxic effects. However, other spe-
cific 5HT uptake inhibitors like citalo-
pram, fluoxctin paroxetine and alaprociate 
downregulate Beta receptors. Trial with 
selective NE uptake blockers like mapro-
toline, nomifensine (inhibits DA uptake 
also) and mianserin , the a2 antagonist, may 
throw clues on mechanism of anxiety disor-
der. 
Beta blockers 
Propranolol relieves somatic signs 
and symptoms of anxiety and can N. PRADHAN  131 
block isoproterenol induced anxiety like 
svmptoms (Carlesson ct al. 1976, Keiholz 
1977). Short term propranolol does not 
prevent lactate induced panic disorders 
(Gorman et al. 1983). The therapeutic ef-
fects of Beta blockers may also be partially 
linked to the effect on the peripheral or-
gans. If high doses of propranolol are 
stopped suddenly panic symptoms may oc-
cur. These groups of drugs effectively in-
crease airway resistance but drugs that do 
not possess significant Beta 2 activity may 
be of value in treatment of anxiety. Beta-1 
(or Cardio selective) blockers are metopro-
lol, atenolol and aceto butolol. In large dos-
age they inhibit all Beta receptors (Prichard 
1978). Therefore, the conclusion on the 
role of Beta-1 receptors in mediating anxie-
ty reaction may be viewed as preliminary. 
Conclusion 
There seems to be a fundamental patho-
physiologic difference between panic di-
sorder and generalised anxiety. The genera-
lised anxiety disorders in most are amelio-
rated by benzodiazepines, whereas the pan-
ic disorder are best treated by TCA and 
MAOl. The antidepressant "term" can mis-
lead clinician that anxious persons with 
panic disorders are not depressed hence do 
not require antidepressants. The new ben-
zodiazepine alprazolam that is effective in 
panic disorder has also differential effect on 
NE system through benzodiazepine recep-
tors. The age old speculation that lactate is 
responsible for neuroaesthema can be used 
to induce panic attacks. Yohimbine has 
been successfully used as a challenging ag-
ent. The future developments in molecular 
pharmacology may help in resolving the 
confusing issues related to these two synd-
romes and hence the therapeutics. 
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